Foghorn Therapeutics Analyst Ratings
Foghorn Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/07/2023 | 117.16% | HC Wainwright & Co. | → $20 | Reiterates | Buy → Buy |
| 07/06/2023 | 8.58% | Morgan Stanley | $13 → $10 | Maintains | Equal-Weight |
| 06/29/2023 | 106.3% | Goldman Sachs | $21 → $19 | Maintains | Buy |
| 06/28/2023 | 117.16% | HC Wainwright & Co. | $20 → $20 | Reiterates | Buy → Buy |
| 06/08/2023 | 117.16% | HC Wainwright & Co. | → $20 | Reiterates | Buy → Buy |
| 05/09/2023 | 52.01% | Wedbush | $15 → $14 | Maintains | Outperform |
| 05/09/2023 | 117.16% | HC Wainwright & Co. | $25 → $20 | Maintains | Buy |
| 04/25/2023 | 106.3% | BMO Capital | $20 → $19 | Maintains | Outperform |
| 04/25/2023 | 62.87% | Wedbush | $20 → $15 | Maintains | Outperform |
| 03/28/2023 | 8.58% | B of A Securities | → $10 | Initiates Coverage On | → Buy |
| 03/10/2023 | 171.44% | HC Wainwright & Co. | → $25 | Reiterates | → Buy |
| 03/10/2023 | 117.16% | Wedbush | $25 → $20 | Maintains | Outperform |
| 01/05/2023 | 117.16% | BMO Capital | → $20 | Initiates Coverage On | → Outperform |
| 11/21/2022 | 52.01% | Morgan Stanley | $15 → $14 | Maintains | Equal-Weight |
| 08/24/2022 | 62.87% | Morgan Stanley | $25 → $15 | Downgrades | Overweight → Equal-Weight |
| 08/10/2022 | 171.44% | HC Wainwright & Co. | $18 → $25 | Maintains | Buy |
| 05/24/2022 | 128.01% | Goldman Sachs | $30 → $21 | Maintains | Buy |
| 05/23/2022 | 171.44% | Morgan Stanley | $26 → $25 | Maintains | Overweight |
| 05/20/2022 | 95.44% | HC Wainwright & Co. | $25 → $18 | Maintains | Buy |
| 12/15/2021 | 182.3% | Morgan Stanley | $23 → $26 | Maintains | Overweight |
| 11/22/2021 | 171.44% | HC Wainwright & Co. | → $25 | Initiates Coverage On | → Buy |
| 03/23/2021 | 149.73% | Morgan Stanley | $24 → $23 | Maintains | Overweight |
| 11/17/2020 | 160.59% | Wedbush | → $24 | Initiates Coverage On | → Outperform |
| 11/17/2020 | 160.59% | Morgan Stanley | → $24 | Initiates Coverage On | → Overweight |
| 11/17/2020 | 193.16% | Goldman Sachs | → $27 | Initiates Coverage On | → Buy |
| 11/17/2020 | — | Cowen & Co. | Initiates Coverage On | → Outperform |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 08/07/2023 | 117.16% | HC Wainwright公司 | →$20 | 重申 | 購買→購買 |
| 07/06/2023 | 8.58% | 摩根士丹利 | $13→$10 | 維護 | 等重 |
| 2023年6月29日 | 106.3% | 高盛 | $21→$19 | 維護 | 買 |
| 2023年6月28日 | 117.16% | HC Wainwright公司 | $20→$20 | 重申 | 購買→購買 |
| 06/08/2023 | 117.16% | HC Wainwright公司 | →$20 | 重申 | 購買→購買 |
| 05/09/2023 | 52.01% | 韋德布什 | $15→$14 | 維護 | 跑贏大盤 |
| 05/09/2023 | 117.16% | HC Wainwright公司 | $25→$20 | 維護 | 買 |
| 04/25/2023 | 106.3% | 蒙特利爾銀行資本 | $20→$19 | 維護 | 跑贏大盤 |
| 04/25/2023 | 62.87% | 韋德布什 | $20→$15 | 維護 | 跑贏大盤 |
| 03/28/2023 | 8.58% | B of A證券 | →$10 | 開始承保 | →購買 |
| 03/10/2023 | 171.44% | HC Wainwright公司 | →$25 | 重申 | →購買 |
| 03/10/2023 | 117.16% | 韋德布什 | $25→$20 | 維護 | 跑贏大盤 |
| 01/05/2023 | 117.16% | 蒙特利爾銀行資本 | →$20 | 開始承保 | →跑贏大盤 |
| 2022年11月21日 | 52.01% | 摩根士丹利 | $15→$14 | 維護 | 等重 |
| 2022年08月24日 | 62.87% | 摩根士丹利 | $25→$15 | 評級下調 | 超重→等重 |
| 2022年08月10日 | 171.44% | HC Wainwright公司 | $18→$25 | 維護 | 買 |
| 2022年05月24日 | 128.01% | 高盛 | $30→$21 | 維護 | 買 |
| 2022年05月23日 | 171.44% | 摩根士丹利 | $26→$25 | 維護 | 超重 |
| 05/20/2022 | 95.44% | HC Wainwright公司 | $25→$18 | 維護 | 買 |
| 2021年12月15日 | 182.3% | 摩根士丹利 | $23→$26 | 維護 | 超重 |
| 2021年11月22日 | 171.44% | HC Wainwright公司 | →$25 | 開始承保 | →購買 |
| 03/23/2021 | 149.73% | 摩根士丹利 | $24→$23 | 維護 | 超重 |
| 11/17/2020 | 160.59% | 韋德布什 | →$24 | 開始承保 | →跑贏大盤 |
| 11/17/2020 | 160.59% | 摩根士丹利 | →$24 | 開始承保 | →超重 |
| 11/17/2020 | 193.16% | 高盛 | →$27 | 開始承保 | →購買 |
| 11/17/2020 | - | 考恩公司 | 開始承保 | →跑贏大盤 |
What is the target price for Foghorn Therapeutics (FHTX)?
福格霍恩治療公司(FHTX)的目標價格是多少？
The latest price target for Foghorn Therapeutics (NASDAQ: FHTX) was reported by HC Wainwright & Co. on August 7, 2023. The analyst firm set a price target for $20.00 expecting FHTX to rise to within 12 months (a possible 117.16% upside). 16 analyst firms have reported ratings in the last year.
2023年8月7日，HC Wainwright&Co.報道了福格霍恩治療公司(納斯達克：FHTX)的最新目標價。這家分析公司將目標價定為20美元，預計FHTX將在12個月內上漲至(可能上漲117.16%)。過去一年，有16家分析公司公佈了評級。
What is the most recent analyst rating for Foghorn Therapeutics (FHTX)?
福格霍恩治療公司(FHTX)的最新分析師評級是多少？
The latest analyst rating for Foghorn Therapeutics (NASDAQ: FHTX) was provided by HC Wainwright & Co., and Foghorn Therapeutics reiterated their buy rating.
福格霍恩治療公司(納斯達克代碼：FHTX)的最新分析師評級是由HC Wainwright&Co.提供的，福格霍恩治療公司重申了他們的買入評級。
When is the next analyst rating going to be posted or updated for Foghorn Therapeutics (FHTX)?
Foghorn治療公司(FHTX)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Foghorn Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Foghorn Therapeutics was filed on August 7, 2023 so you should expect the next rating to be made available sometime around August 7, 2024.
分析師在進行了廣泛的研究後得出股票評級，其中包括查閱公共財務報表，與福格霍恩治療公司的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。Foghorn治療公司的上一次評級是在2023年8月7日提交的，所以你應該預計下一次評級將在2024年8月7日左右的某個時候提供。
Is the Analyst Rating Foghorn Therapeutics (FHTX) correct?
分析師對福格霍恩治療公司(FHTX)的評級正確嗎？
While ratings are subjective and will change, the latest Foghorn Therapeutics (FHTX) rating was a reiterated with a price target of $0.00 to $20.00. The current price Foghorn Therapeutics (FHTX) is trading at is $9.21, which is within the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的FHTX評級被重申，目標價在0.00美元至20.00美元之間。福格霍恩治療公司(FHTX)目前的交易價格為9.21美元，在分析師的預測範圍內。
譯文內容由第三人軟體翻譯。